Aspirin Use in Primary Prevention for Patients with Diabetes

Introduction to Aspirin Guidelines

The American College of Cardiology and American Heart Association downgraded aspirin for primary prevention to Class IIb, recommending it "may be considered" only for adults aged 40-59 years with ≥10% 10-year ASCVD risk and no increased bleeding risk, noting the net benefit is small 1
The American Diabetes Association states aspirin "may be considered" for primary prevention in diabetic patients aged ≥50 years with at least one additional major cardiovascular risk factor, acknowledging the controversial evidence 2, 1

For patients with diabetes, age ≥50 years with at least one additional major cardiovascular risk factor may be considered for aspirin 75-162 mg daily, but recent evidence shows this benefit is modest at best 1, 2
The decision to use aspirin should be based on a comprehensive risk-benefit analysis, including assessment of bleeding risk factors such as age >70 years, history of GI bleeding, concurrent medications that increase bleeding, and uncontrolled hypertension 1
Patients with uncontrolled diabetes, like the one presented with an A1c of 9.7%, have a higher risk of cardiovascular and bleeding events, making the risk-benefit calculation less favorable for aspirin use 3

Optimizing glycemic control is crucial, as an A1c of 9.7% represents a significant modifiable risk factor that should be addressed immediately 3
Implementing continuous glucose monitoring (CGM) and intensifying blood pressure control to <140/90 mmHg (or <130/80 mmHg per newer guidelines) are recommended 3, 2
Optimizing lipid management with appropriate statin therapy has stronger evidence for cardiovascular risk reduction than aspirin in primary prevention 3, 5

Even low-dose aspirin increases major GI bleeding risk by 60% (relative risk 1.6), with absolute rates of 2-4 per 1,000 middle-aged adults over 5 years 2, 1
The presence of bleeding risk factors should be carefully evaluated before considering aspirin therapy 1

Aspirin may be considered if the 10-year ASCVD risk is ≥10%, there are no bleeding risk factors present, blood pressure is controlled, and the patient demonstrates medication adherence, with a dose of 75-81 mg daily 1, 2